Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exo… Read more
Sarepta Therapeutics Inc (SRPT) - Total Assets
Latest total assets as of September 2025: $3.49 Billion USD
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) holds total assets worth $3.49 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sarepta Therapeutics Inc - Total Assets Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sarepta Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Sarepta Therapeutics Inc's total assets of $3.49 Billion consist of 77.6% current assets and 22.5% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.8% |
| Accounts Receivable | $649.73 Million | 16.4% |
| Inventory | $749.96 Million | 18.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $26.89 Million | 0.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Sarepta Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sarepta Therapeutics Inc's current assets represent 77.6% of total assets in 2024, an increase from 39.1% in 1995.
- Cash Position: Cash and equivalents constituted 27.8% of total assets in 2024, down from 30.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 1995.
- Asset Diversification: The largest asset category is inventory at 18.9% of total assets.
Sarepta Therapeutics Inc Competitors by Total Assets
Key competitors of Sarepta Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Sarepta Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Sarepta Therapeutics Inc generates 0.48x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Sarepta Therapeutics Inc generates $5.94 in net profit.
Sarepta Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.95 | 3.84 | 5.97 |
| Quick Ratio | 1.79 | 3.03 | 5.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.80 Billion | $ 1.99 Billion | $ 2.07 Billion |
Sarepta Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sarepta Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.41 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 21.4% |
| Total Assets | $3.96 Billion |
| Market Capitalization | $1.67 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sarepta Therapeutics Inc's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Sarepta Therapeutics Inc's assets grew by 21.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Sarepta Therapeutics Inc (1995–2024)
The table below shows the annual total assets of Sarepta Therapeutics Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.96 Billion | +21.40% |
| 2023-12-31 | $3.26 Billion | +4.35% |
| 2022-12-31 | $3.13 Billion | -0.62% |
| 2021-12-31 | $3.15 Billion | +5.47% |
| 2020-12-31 | $2.98 Billion | +63.74% |
| 2019-12-31 | $1.82 Billion | +11.01% |
| 2018-12-31 | $1.64 Billion | +25.54% |
| 2017-12-31 | $1.31 Billion | +208.41% |
| 2016-12-31 | $424.10 Million | +54.91% |
| 2015-12-31 | $273.78 Million | -7.20% |
| 2014-12-31 | $295.03 Million | +1.19% |
| 2013-12-31 | $291.57 Million | +42.23% |
| 2012-12-31 | $204.99 Million | +277.05% |
| 2011-12-31 | $54.37 Million | +18.25% |
| 2010-12-31 | $45.98 Million | -23.41% |
| 2009-12-31 | $60.03 Million | +135.07% |
| 2008-12-31 | $25.54 Million | -33.91% |
| 2007-12-31 | $38.64 Million | -5.44% |
| 2006-12-31 | $40.86 Million | -27.56% |
| 2005-12-31 | $56.41 Million | +97.79% |
| 2004-12-31 | $28.52 Million | -39.51% |
| 2003-12-31 | $47.15 Million | +64.82% |
| 2002-12-31 | $28.60 Million | -15.41% |
| 2001-12-31 | $33.82 Million | -3.63% |
| 2000-12-31 | $35.09 Million | +172.00% |
| 1999-12-31 | $12.90 Million | +26.47% |
| 1998-12-31 | $10.20 Million | -45.74% |
| 1997-12-31 | $18.80 Million | +347.62% |
| 1996-12-31 | $4.20 Million | +82.61% |
| 1995-12-31 | $2.30 Million | -- |